附件99.1
Mallinckrodt达成协议出售Therakos® 以92500美元万的价格实现业务对客户风险投资
资产剥离推进了Mallinckrodt的战略重点，以优化资本结构并专注于核心专业领域
Mallinckrodt将利用净收益将净债务减少50%以上
CVC带来资源和专业知识以进一步 开发Therakos并将其商业化
都柏林和卢森堡-2024年8月5日-全球专业制药公司Mallinckrodt plc(“Mallinckrodt”或“公司”)和世界领先的投资公司之一CVC Capital Partners(“CVC”)今天宣布，他们已达成最终协议。1根据该协议，CVC 资本伙伴基金IX 将以92500美元万的收购价收购公司的Therakos业务，但须遵循惯例 调整。
Therakos是一种完全集成的体外光分离术(ECP)递送系统，用于自体免疫调节治疗。已获准在美国、加拿大、欧洲、日本、澳大利亚和拉丁美洲使用， 它是医疗保健提供者和患者治疗一系列免疫相关疾病的首选平台。CVC在医疗保健方面拥有深厚的专业知识，并拥有涵盖制药、医疗技术和医疗保健服务的全球生命科学业务组合。该公司打算 在Therakos的持续研究、开发、适应症扩展和地理扩展方面进行额外投资。
根据协议条款，在Therakos 上工作的关键员工将与业务一起过渡，并继续支持该产品及其利益相关者。
凯瑟琳·佩蒂和菲尔·罗宾逊(Phil Robinson)代表CVC医疗团队表示：“我们看到了扩大Therakos的适应症、进入新地区并将这种创新疗法带给世界各地更多患者的重大机遇。我们期待着与才华横溢的Therakos团队密切合作，并将这种具有无与伦比的功效、安全性和耐受性的同类最佳ECP系统添加到我们的医疗保健业务组合中。“
Mallinckrodt首席执行官Siggi Olafsson、总裁和首席执行官Siggi Olafsson表示：“今天的声明强调了我们致力于执行我们的战略优先事项，并为我们的利益相关者创造价值。”这笔交易为Therakos业务提供了一个投资于其持续增长的理想合作伙伴，我们 期待着与CVC密切合作，为患者、医疗保健提供者、合作伙伴和员工的利益过渡Therakos。 我感谢Therakos团队不断致力于改善患者的生活。
Mallinckrodt打算使用交易净收益将其净债务减少 50%以上。交易预计将在2024年第四季度完成，这取决于监管部门的批准和 其他常规完成条件。
顾问
Lazard担任Mallinckrodt的财务顾问，Wachtell，Lipton，Rosen&Katz担任主要法律顾问，Arthur Cox担任爱尔兰法律顾问，A&O Searman 担任其他国际地区的法律顾问。
1CVC还作出了不可撤销的承诺，收购了经营Therakos业务的法国公司Therakos(France) SAS的股份。与CVC就Therakos(France)SAS股份达成的最终协议将在满足当地信息要求后生效。
瑞银将与富而德(Freshfield)(法律顾问)、普华永道(PWC)(金融)和坎迪西奇(Candesic)一起担任CVC的财务顾问。
关于马林克洛特
Mallinckrodt是一家全球性企业，由多家全资子公司组成，这些子公司开发、制造、营销和分销特种药品和疗法。该公司的专业 品牌可报告领域的重点领域包括神经科、风湿科、肝科、肾科、肺科、眼科和肿瘤科等专科领域的自身免疫性和罕见疾病；免疫疗法和新生儿呼吸系统危重护理疗法；止痛药；以及胃肠 产品。其特种仿制药可报告部门包括特种仿制药和活性药物成分。要了解有关Mallinckrodt的更多信息，请访问www.mallinckrodt.com。
Mallinckrodt使用其网站作为发布重要公司信息的渠道，例如新闻稿、投资者演示文稿和其他财务信息。它还利用其网站加快 公众在发布新闻稿或向美国证券交易委员会(“美国证券交易委员会”)提交披露相同信息的新闻稿或文件之前 获取有关公司的关键时间信息。因此，投资者应 查看网站的投资者关系页面，以获取重要且时间紧迫的信息。网站访问者还可以注册 以收到自动电子邮件和其他通知，当网站的投资者关系页面上有新信息时提醒他们。
CVC，传播总监
nboard@cvc.com
Mallinckrodt、“M”品牌标志和Mallinckrodt Pharmaceuticals 徽标是Mallinckrodt公司的商标。其他品牌是Mallinckrodt公司或其各自所有者的商标。© 2024。
Statements in this press release that are not strictly historical, including statements regarding future financial condition and operating results, expected product launches, legal, economic, business, competitive and/or regulatory factors affecting Mallinckrodt’s businesses, the ongoing strategic review, and any other statements regarding events or developments Mallinckrodt believes or anticipates will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties.
There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: the parties’ ability to satisfy the conditions to the divestiture of the Therakos business, including required regulatory approvals, and the ability to complete the divestiture on the anticipated timeline or at all; the potential impact of the divestiture on our businesses and the risk that consummating the divestiture may be more difficult, time-consuming and costly than expected; changes in Mallinckrodt’s board of directors, business strategy and performance; Mallinckrodt’s evaluation of the assets across its portfolio, and its related pursuit of any divestiture opportunities including completion of the sale of Therakos; the exercise of contingent value rights by the Opioid Master Disbursement Trust II (the “Trust”); Mallinckrodt’s repurchases of debt securities; the liquidity, results of operations and businesses of Mallinckrodt and its subsidiaries; governmental investigations and inquiries, regulatory actions, and lawsuits, in each case related to Mallinckrodt or its officers; Mallinckrodt’s contractual and court-ordered compliance obligations that, if violated, could result in penalties; historical commercialization of opioids, including compliance with and restrictions under the global settlement to resolve all opioid-related claims; matters related to Acthar Gel, including the settlement with governmental parties to resolve certain disputes and compliance with and restrictions under the related corporate integrity agreement; the ability to maintain relationships with Mallinckrodt’s suppliers, customers, employees and other third parties following the emergence from the 2023 bankruptcy proceedings, as well as perceptions of the Company's increased performance and credit risks associated with its constrained liquidity position and capital structure; the possibility that Mallinckrodt may be unable to achieve its business and strategic goals even now that the emergence from the 2023 bankruptcy proceedings was successfully consummated; the non-dischargeability of certain claims against Mallinckrodt as part of the bankruptcy process; developing, funding and executing Mallinckrodt's business plan; Mallinckrodt’s capital structure since its emergence from the 2023 bankruptcy proceedings; scrutiny from governments, legislative bodies and enforcement agencies related to sales, marketing and pricing practices; pricing pressure on certain of Mallinckrodt’s products due to legal changes or changes in insurers’ or other payers’ reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; the reimbursement practices of governmental health administration authorities, private health coverage insurers and other third-party payers; complex reporting and payment obligations under the Medicare and Medicaid rebate programs and other governmental purchasing and rebate programs; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; changes in or failure to comply with relevant laws and regulations; any undesirable side effects caused by Mallinckrodt’s approved and investigational products, which could limit their commercial profile or result in other negative consequences; Mallinckrodt’s and its partners’ ability to successfully develop, commercialize or launch new products or expand commercial opportunities of existing products, including Acthar Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector and the INOmax Evolve platform; Mallinckrodt’s ability to successfully identify or discover additional products or product candidates; Mallinckrodt’s ability to navigate price fluctuations; competition; Mallinckrodt’s and its partners’ ability to protect intellectual property rights, including in relation to ongoing and future litigation; limited clinical trial data for Acthar Gel; the timing, expense and uncertainty associated with clinical studies and related regulatory processes; product liability losses and other litigation liability; material health, safety and environmental liabilities; business development activities or other strategic transactions; attraction and retention of key personnel; the effectiveness of information technology infrastructure, including risks of external attacks or failures; customer concentration; Mallinckrodt’s reliance on certain individual products that are material to its financial performance; Mallinckrodt’s ability to receive sufficient procurement and production quotas granted by the U.S. Drug Enforcement Administration; complex manufacturing processes; reliance on third-party manufacturers and supply chain providers and related market disruptions; conducting business internationally; Mallinckrodt’s ability to achieve expected benefits from prior or future restructuring activities; Mallinckrodt’s significant levels of intangible assets and related impairment testing; natural disasters or other catastrophic events; Mallinckrodt’s substantial indebtedness and settlement obligation, its ability to generate sufficient cash to reduce its indebtedness and its potential need and ability to incur further indebtedness; restrictions contained in the agreements governing Mallinckrodt’s indebtedness and settlement obligation on Mallinckrodt’s operations, future financings and use of proceeds; actions taken by third parties, including the Company's creditors, the Trust and other stakeholders; Mallinckrodt’s variable rate indebtedness; Mallinckrodt's tax treatment by the Internal Revenue Service under Section 7874 and Section 382 of the Internal Revenue Code of 1986, as amended; future changes to applicable tax laws or the impact of disputes with governmental tax authorities; the impact of Irish laws; the impact on the holders of Mallinckrodt’s ordinary shares if Mallinckrodt’s were to cease to be a reporting company in the United States; the comparability of Mallinckrodt’s post-emergence financial results and the projections filed with the Bankruptcy Court; and the lack of comparability of Mallinckrodt’s historical financial statements and information contained in its financial statements after the adoption of fresh-start accounting following emergence from the 2023 bankruptcy proceedings.
The “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of Mallinckrodt’s Annual Report on Form 10-K for the fiscal year ended December 29, 2023, Quarterly Report on Form 10-Q for the quarterly period ended March 29, 2024, Quarterly Report on Form 10-Q for the quarterly period ended June 28, 2024, to be filed with the SEC, and other filings with the SEC, which are available from the SEC’s website (www.sec.gov) and Mallinckrodt's (www.mallinckrodt.com), identify and describe in more detail the risks and uncertainties to which Mallinckrodt’s businesses are subject. There may be other risks and uncertainties that we are unable to predict at this time or that we currently do not expect to have a material adverse effect on our business. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. Given these uncertainties, one should not put undue reliance on any forward-looking statements.
Mallinckrodt Contacts
Investor Relations
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Patient Advocacy
Derek Naten
Vice President, Government Affairs
202-459-4143
derek.naten@mnk.com
Media
Michael Freitag / Aaron Palash / Aura Reinhard
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
CVC Contacts
Nick Board
CVC, Director Communications
nboard@cvc.com
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2024.